Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Assetmark Inc.

Assetmark Inc. lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 954.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 327 shares of the life sciences company’s stock after purchasing an additional 296 shares during the quarter. Assetmark Inc.’s holdings in Illumina were worth $44,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in ILMN. Janney Montgomery Scott LLC lifted its position in Illumina by 73.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 6,580 shares of the life sciences company’s stock valued at $858,000 after purchasing an additional 2,783 shares during the last quarter. KBC Group NV raised its stake in Illumina by 2.1% during the 3rd quarter. KBC Group NV now owns 42,516 shares of the life sciences company’s stock valued at $5,544,000 after acquiring an additional 859 shares in the last quarter. Huntington National Bank grew its stake in shares of Illumina by 29.4% in the third quarter. Huntington National Bank now owns 515 shares of the life sciences company’s stock worth $67,000 after purchasing an additional 117 shares in the last quarter. Metis Global Partners LLC grew its stake in shares of Illumina by 9.1% in the third quarter. Metis Global Partners LLC now owns 3,575 shares of the life sciences company’s stock worth $466,000 after purchasing an additional 299 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Illumina by 7.0% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,978 shares of the life sciences company’s stock valued at $649,000 after purchasing an additional 326 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ILMN shares. Guggenheim reduced their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, March 5th. TD Cowen cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their price target for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Piper Sandler raised their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Finally, HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and an average target price of $140.90.

Illumina Stock Up 1.8 %

Shares of Illumina stock opened at $85.60 on Friday. Illumina, Inc. has a 12-month low of $80.18 and a 12-month high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $113.52 and a two-hundred day moving average price of $129.88. The stock has a market capitalization of $13.56 billion, a P/E ratio of -11.15, a PEG ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.